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ABSTRACT
Objective: This study aimed at analyzing drug-related problems (DRPs) in hospitalized geriatric patients with diabetes mellitus.
Methods: We prospectively collected data of 26 hospitalized geriatric patients at the Gatot Soebroto Army Hospital (age, >60 year) who underwent 
inpatient treatment for at least 1 month between February and April 2015. Readable data were obtained from prescriptions, medical records, and 
index card/nurses records. We obtained data on 299 drug treatments for 26 patients and identified 166 DRPs. These were analyzed based on the 
Pharmaceutical Care Network Europe Version 6.2.
Results: The percentage of treatment effectiveness (50.6%) and adverse drug reactions (49.4%) was predominantly due to an inappropriate drug–
drug or drug–food combination, including the incidence of drug interactions (20.4%).
Keywords: Adverse reaction, Drug-related problem, Gatot Soebroto Army Hospital, Geriatric, Treatment effectiveness.
INTRODUCTION
Indonesia ranks 4th among the countries with the largest number of 
diabetes mellitus (DM) cases worldwide, after India, China, and US, 
based on information obtained from the World Health Organization 
in 2006. In 2009, the International Diabetes Federation predicted an 
increase in the number of individuals with DM in Indonesia from 7 to 
12 million by 2030. Currently, there are two therapeutic approaches for 
individuals with DM - with or without drugs. Treatment without drugs 
is based on specific dietary guidelines, known as nutritional therapy, 
and physical activity. If this approach does not lead to the therapeutic 
goal, then drugs are introduced. Specifically, pharmacological steps can 
be in the form of insulin therapy, oral hypoglycemic drug therapy, or 
a combination of both [1-3]. Insulin is the treatment for patients with 
type 1 DM, whereas oral hypoglycemic drugs are intended to help in 
the treatment of patients with type II DM. The management of DM 
with drug therapy may lead to drug-related problems (DRPs) and an 
inability to achieve therapeutic goals. Insulin administration may cause 
hypoglycemia [1,4]. Adverse drug effects are a subset of DRP issues.
DRP is a condition associated with drug therapy that may potentially 
interfere with the desired health clinical outcomes [5]. Research 
conducted in French hospitals has suggested that frequent DRP is 
the administration of drugs contraindicated with patients’ condition 
(21.3%), improper administration (20.6%), subtherapeutic dose 
(19.2%), and drug interactions (12.6%). An Indonesian study has 
shown that 78.2% of geriatric patients experienced DRP during 
hospitalization [6]. Older adults are particularly vulnerable to DRP for 
the following two main reasons: (1) Age-related physiological changes 
may alter the pharmacokinetic and pharmacodynamic properties of the 
drug and (2) the presence of comorbidities and the use of some drugs 
referred as polypharmacy. Polypharmacy relates to the use of multiple 
medications and treatments through various administrative routes 
exceeding clinical indications [7-10].
There are several classifications of DRP, including those according to 
Strand, Granada II, Pharmaceutical Care Network Europe (PCNE), 
and Apoteket AB. PCNE classifies DRP based on major domains and 
subdomains in detail [11]. The latest PCNE classification is a revised 
2010 known as “the classification PCNE V6.2.” PCNE V6.2 has been 
unveiled by the Ministry of Health as a guide for DRP identification 
in current guidelines for pharmacists [12]. Gatot Soebroto Army 
Hospital is a Class A hospital owned by the Government of the Republic 
of Indonesia. Gatot Soebroto Army Hospital has medical services 
specialized in internal disease providing care for metabolic endocrine 
geriatric/diabetes. This study aimed at analyzing DRPs in geriatric 
patients with DM since Gatot Soebroto Army Hospital serves a high 
number of geriatric patients with DM.
METHODS
We performed a descriptive analytic research. Data were prospectively 
collected. Specifically, we observed secondary data in the form of 
drug prescriptions, medical records, and cardiac/nurse records. Data 
collected in this study originated from geriatric inpatients with DM 
treated at the Gatot Soebroto Army Hospital between February and 
April 2015.
Data matching the inclusion criteria were collected either through 
the pharmacy (for inpatient prescriptions) or through the hospital 
administration and registration office (medical record number and 
cardiac/nurse notes). DRP was analyzed using available literature, 
including Pharmacotherapy A Pathophysiologic Approach, 7th edition; 
Drug Information Handbook, 17th edition; Geriatric Dosage Handbook 
in 2005; Journal of Pharmacy of Clinic; MIMS; and ISO 2014. In addition, 
a specialized search in drug interaction was conducted using software 
Micromedex®.
Patients’ data collected included the name, medical record number, 
age, diagnosis, complaints, prescribed medications, dosage regimen, 
and treatment duration. Data were reported on pre-prepared data 
collection sheets. We identified the presence of DRP by filling out a list 
of contents based on the PCNE V6.2 referring to the literature with the 
main domains of therapeutic effectiveness and adverse drug reactions 
(ADRs).
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RESULTS
Characteristics of research sample
Data were obtained from observation of patients’ medical records. 
Collected information included sex, DM type, hospital length, history 
of DM, and DM complications. Characteristics of the study group are 
shown in Table 1.
DRPs in geriatric patients with DM
Data were prospectively collected with the total sampling method. Of the 
total population evaluated, 26 individuals were found to meet the inclusion 
criteria. Post-analysis, we observed that all the patients evaluated had DRP. 
Specifically, 55% had an actual problem and 45% had a potential problem. 
Among the 299 drug therapies underwent by the 26 patients, 166 DRPs 
were identified. Importantly, among DRPs, therapeutic effectiveness 
problems had a higher frequency than ADRs (50.6% vs. 49.4%, 
respectively; Table 2 and Fig. 1). Percentages of treatment effectiveness 
and ADR subdomain problems are shown in Figs. 2 and 3.
DISCUSSION
Therapeutic effectiveness problems
Ineffective medication or treatment failure
The number of cases with ineffective drug or failed treatment amounted 
to 37. Possible causes were the use of a lower amount of drug than 
prescribed (underused), drug administration occurred at a lower 
frequency than prescribed (under-administered), inappropriate drug 
selection, incorrect combination of drug–drug and drug–food leading to 
drug interactions, low doses, and patients’ deterioration/improvement 
requiring dose adjustment.
Ceftriaxone was either underused or under-administered. Specifically, 
ceftriaxone was to be administered 1×2 g for 5 day. However, in three 
patients, the antibiotic was not administered as prescribed. In one of the 
patients, this resulted in a foot infection that did not improve. Due to the 
length of obtaining results from a culture (5 days), empirical antibiotics 
are given as initial treatment before culture results are obtained. These 
antibiotics should be changed if the results of the bacterial culture show 
resistance to the empirical antibiotics. However, despite the laboratory 
results, antibiotic replacement does not take place in some cases. 
Patients’ condition did not improve following the empirical antibiotic 
probably because of unavailability or high cost of an appropriate 
antibiotic, or to the common knowledge that in most cases, empirical 
antibiotics are sufficient to treat the patients’ condition.
To date, standardized guidelines on empirical antibiotics’ use are 
unavailable. Patients treated with empirical antibiotics should be 
evaluated for 48–72 h. In case of improvement, antibiotics should be 
administered until the patient shows a good clinical response and 
discontinued after 7 days [13].
Treatment failure because of drug interaction occurred as a result of the 
concurrent administration of aspirin–valsartan (salicylate–angiotensin 
II receptor blocker). Specifically, the interaction causes a decrease of 
valsartan’s antihypertensive effect so that the patients’ blood pressure 
continues between systole (140 and 159 mmHg) and diastole (90–
99 mmHg).
Fig. 1: Proportions of primary domain problems (Pharmaceutical 
Care Network Europe V6.2) (n=166)
Fig. 2: Percentages of treatment effectiveness subdomain problems (Pharmaceutical Care Network Europe V6.2) (n=84)






Type 1 DM 0 (0.0)
Type 2 DM 26 (100.0)











Diabetic ketoacidosis 7 (26.9)




Heart blood vessels 3 (11.5)
Peripheral blood vessels 0 (0.0)
Brain blood vessels 3 (11.5)
Microangiopathy
Diabetic retinopathy 0 (0.0)
Diabetic nephropathy 7 (26.9)
Neuropathy 6 (23.1)
Diabetic foot 6 (23.1)
Hypertension 7 (26.9)
Description: *One patient may experience more than one diabetic complication. 
DM: Diabetes mellitus
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An ineffective drug case occurred in a hypertensive patient receiving 
dose adjustment of candesartan from 1/16 to 1×4 mg due to improved 
blood pressure by the previous one measure. Unfortunately, patients’ 
blood pressure increased again in the subsequent checks and there was 
no dose adjustment (increased dose) for this condition until the end of 
treatment.
A cause of ineffective drug or failed treatment while on DM medications is 
the low dose of insulin. In general, geriatric patients who enter a Class A 
hospital have been previously unsuccessfully treated with oral hypoglycemic 
drugs, which were substituted by insulin. Before administering a fixed dose 
of insulin to the patient, insulin is initially provided based on the sliding 
scale method, with a protocol of blood glucose range on a large scale.
Fig. 3: Percentages of adverse drug reactions subdomain problems (Pharmaceutical Care Network Europe V6.2) (n=82)
Table 2: Subdomain classification cause (PCNE V6.2) (n=181)
Code Primary domain Number of 
problems (%)
C1 P1. Drug selection 91 (50.3)
C1.1 Selection of inappropriate drugs (not for the most appropriate indications) includes the use of contraindicated 
drugs
13 (7.2)
C1.2 No indications of drug use or indications of drugs are unclear 7 (3.9)
C1.3 Inappropriate drug–food or drug–drug combinations, including in drug interactions 37 (20.4)
C1.4 Inappropriate duplication of therapy or inactive ingredients 0 (0.0)
C1.5 The drug is indicated but not prescribed 6 (3.3)
C1.6 Many drugs (therapeutic groups or different active ingredients) are prescribed for the same indication 10 (5.5)
C1.7 There are more cost-effective drugs available 0 (0.0)
C1.8 Synergistic/preventive drugs required are not prescribed 0 (0.0)
C1.9 There are newly indicated drugs but have not been prescribed 18 (9.9)
C2 Dosage form selection 0 (0.0)
C2.1 Incorrect dosage form of drugs 0 (0.0)
C3 Dosage selection 47 (26.0)
C3.1 The dose of the drug is too low 9 (5.0)
C3.2 The dose of the drug is too high 9 (5.0)
C3.3 Dosage settings are infrequent 7 (3.9)
C3.4 Dosage settings are too frequent 10 (5.5)
C3.5 No blood monitoring was performed 0 (0.0)
C3.6 Pharmacokinetic-related issues that require dose adjustment 8 (4.4)
C3.7 Impairment/improvement of sick conditions requiring dose adjustment 4 (2.2)
C4 Duration of treatment determination 0 (0.0)
C4.1 Duration of treatment is too short 0 (0.0)
C4.2 Duration of treatment is too long 0 (0.0)
C5 Drug usage process 41 (22.7)
C5.1 The timing of drug use or dosage interval is not appropriate 9 (5.0)
C5.2 Drug underused/under administered 22 (12.2)
C5.3 Drug overused or over administered 0 (0.0)
C5.4 Drugs not taken or not administered 10 (5.5)
C5.5 Wrong drug taken/administered 0 (0.0)
C5.6 Drug abuse (drug use does not conform to official designation) 0 (0.0)
C5.7 Patients cannot use drugs or dosage forms according to the rules 0 (0.0)
C6 Logistics (pharmacy) 1 (0.6)
C6.1 The prescribed drug is not available 0 (0.0)
C6.2 Prescribing error 1 (0.6)
C6.3 Drug dispensing error 0 (0.0)
C7 Patient 1 (0.6)
C7.1 Patient forgot to drink the medicine 0 (0.0)
C7.2 Patients use unnecessary drugs 0 (0.0)
C7.3 Patients eat foods that interact with medications 1 (0.6)
C7.4 Patient medication storage is not appropriate 0 (0.0)
C8 Others 0 (0.0)
C8.1 Other specific causes 0 (0.0)
C8.2 Other unclear causes 0 (0.0)
Description: One problem domain may comprise more than one cause (maximum three) (PCNE, 2010). PCNE: Pharmaceutical Care Network Europe
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The commonly used dose of sliding scale has a minimum dose of 4 μ 
and a maximum dose of 20 μ/6 h. This method is used for a maximum 
of 5 days of treatment. An ineffective scale results in an indeterminate 
fixed dose of insulin leading to an unclear picture of the patients’ blood 
sugar level (BSL) even until the end of the treatment, resulting in the 
patients’ BSL not improving.
We observed that, occasionally, the sliding scale method was not 
performed. Instead, the fixed dose method was used, without following 
treatment guidelines. Specifically, a patient weighed 55 kg and was 
given insulin Novorapid® 3×4 μ in the absence of oral hypoglycemic 
drugs. The most commonly used type of insulin was aspart (rapid-
acting, from Novorapid®). Dosage for both type 1 and type 2 DMs was 
0.5–1 μ kg/day. Therefore, a patient weighing 55 kg should receive a 
minimum dose per day of 27.5 μ. We observed that BSL in most patients 
until following checkup was >200 mg/dL.
Drug effects were not optimal
In 20 cases, medication effects were not optimal. Specifically, of 
20 cases, 14 did not receive DM drug therapy, whereas six received the 
therapy in the form of insulin. We listed four reasons for the effects of 
non-optimal drugs, namely low-frequency dosing arrangements, lower 
dosage than advised in the guidelines (underused), drug administration 
less frequently than advised in the guidelines (under-administered), 
and dosage which was too low.
We observed that a suboptimal medication effect in DM therapy is 
caused by doses of insulin too low. In our case, the patients’ BSL 
improved from before hospital admission but remained high at 
≥200 mg/dL until sometime after insulin injections. Non-DM drugs 
with potentially ineffective drug effects are histamine H2 antagonist, 
vitamins, proton-pump inhibitors, NSAIDs, angiotensin-converting-
enzyme (ACE) inhibitors, antiemetics, and antibiotics generally caused 
by drug underuse, under-administration, and infrequent dosing 
arrangements.
Ranitidine injection (histamine H2 antagonist) effect is suboptimal due 
to infrequent dosage regulation. Ranitidine dose regimen prescribed 
was 2×50 mg i.v.; however, 50 mg of the drug should be administered 
every 6–8 h for patients not suffering from kidney disease.
The effect of metoclopramide as antiemetics was suboptimal due to 
their underuse or underadministration. Specifically, metoclopramide 
was prescribed at the dosage of 2×1 tablet according to records we 
observed. On the contrary, patients with nausea are usually prescribed 
at the dosage of 3×1 tablet. As a consequence, after 3 days of treatment, 
nausea complaints were not reduced.
Effects of inappropriate drug (idiosyncrasies)
Idiosyncrasy is a drug effect occurring in certain individuals. It is 
different from the effects caused by genetic abnormalities. For example, 
morphine in most people causes depression effects, while in certain 
individuals, especially women, it can cause excitation [14]. DRP with 
the wrong drug subdomain (idiosyncrasies) was not found in our study 
group.
In 26 patients, DRPs were found, with indications that were not treated. 
We observed that the lack of treatment was due to the following three 
causes: New indications arise and previously chosen drugs were not 
prescribed; drugs were either not taken or administered; and despite 
the indications, drugs were not prescribed. Cases with indications that 
are not treated can be often found in non-DM conditions. Assessments 
are done based on laboratory data and specific details of the patient.
The patients’ rapidly changing BSLs require routine monitoring 
and medications at specific intervals. We observed that missed 
routine monitoring is the primary cause for the lack of treatment in 
the DM patients included in our study group. Of note, one case was 
representative for many other DM cases. Specifically, the patient 
was admitted to the hospital with BSL (19.30 [9/3/15]), for which 
46 mg/dL of D 40% IV bolus were administered along with a paired 
infusion of D10% 15 gtt/min. The DM drug was discontinued. BSL was 
examined at 2-time points - 23.00 (9/3/15) with 107 mg/dL and 02.00 
with 264 mg/dL. Once the condition was cleared, no treatment for 
hyperglycemia was administered.
Another example of unaddressed indication is the case of a patient 
who was identified with a new indication; however, the drug to treat it 
was not prescribed. Based on our observations of unwritten admission 
diagnosis, the patient was anemic. Following a few days of treatment, 
the patients’ blood work showed hemoglobin level of 9.9 g/dL (normal 
value, 12–16 g/dL); however, no therapy was given to address the 
condition.
A number of indications remain untreated due to the failure of taking 
the drug or missed administration because the time of administration 
is not listed in the Kardex. For example, paracetamol was prescribed to 
a patient due to fever, but the time of administration of the drug was not 
listed in the Kardex.
Finally, we observed the case of a patient who was not treated despite 
the presence of indicators. Specifically, on admission, the patient 
underwent laboratory a checkup. Results showed a leukocyte value of 
13,210 μL (normal value: 4,800–10,800 μL). These results indicate the 
presence of an infection; however, no drug was prescribed.
ADRs
Patients suffer ADR not allergies
We observed 60 incidences of patients suffering from non-allergic 
ADR. ADR is not an allergy. It is caused by the combination of drugs, 
inappropriate medications, drug interactions, and the use of several 
drugs (different therapeutic group or active ingredients) prescribed 
for the same indication. ADR is often seen following the administration 
of ranitidine with a dose of 2×2 ml i.v. and omeprazole with a dose of 
1×40 mg or in combination with other types of drugs such as sucralfate 
or rebamipide. Patients complain of abdominal pain; however, no 
further examination such as gastroscopy is performed to determine the 
condition of gastric or duodenal ulcers.
Yet when omeprazole is discontinued, the use of ranitidine alone 
sees the worsening of the gastric ulcers [15]. Another example can be 
observed in the case of the administration of drugs for hypertension. 
Common therapeutic approach consists of bisoprolol (β-blocker 
and β1-selective) and ramipril (ACE inhibitor). Specifically, a patient 
has a history of hypertension with blood pressure before the drug 
administration ranging between a systolic of 120 and 139 mmHg and 
a diastolic of 80 and 89 mmHg. A potential UDR that may arise when 
treating this patient with both drugs is hypotension.
The potential for non-allergic ADR may be caused by the absence of 
an indication of drug use or indications of unclear drugs such as in the 
case of ranitidine or omeprazole and metoclopramide or ondansetron. 
Based on laboratory results or patient complaints, there is no indication 
whatsoever related to drug administration. UDR is possibly caused by 
ranitidine, in line with the condition of the patient, which is nausea, 
vomiting, and abdominal discomfort.
Patients with sudden hypoglycemia will have ADR resulting from too 
high doses. However, if the patient is still conscious, restoring the 
patients’ blood glucose condition immediately by giving D40% i.v. 
would result in the patients’ BSL being too high >250 mg/dL. Selection 
of inappropriate drugs (i.e., drugs used not for the recommended 
indication) includes the use of contraindicated drugs that cause ADR. 
Examples of this instance are patients with hyperkalemia shown by 
laboratory tests, who were prescribed sustained-release potassium 
dosage form indicated for hypokalemia. Patients will continue to show 
hyperkalemia in the following days. Patients were given a D5% infusion 
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post-hypoglycemia; however, the patients’ BSL was not monitored until 
it reached 403 mg/dL. This case is an example of UDR due to the absence 
of a dose adjustment. This condition is classified as a subdomain 
causing deterioration/improvement of ill conditions requiring dose 
adjustment. Patients were administered Novorapid® with instructions 
to administer 3×10 μ at 6:00 am, 12:00, and 17:00 pm. Despite the first 
two injections afternoon BSL (55 mg/dL), checks showed that patients 
were experiencing hypoglycemia. This patients’ ADR was likely due to 
frequent dose regulation. The appropriate insulin dosage for patients 
weighing 40 kg ranges from 20 to 40 μ/day.
We observed the improper timing of drug use or dosing interval 
potentially causing UDR following the administration of a prescribed 
antihypertensive drug ramipril 1×1 mg. This drug was administered 
in conjunction with Novorapid® at 06.00, potentially causing 
hypoglycemia.
UDR in patients eating foods that interact with drugs was seen when 
drinking sugar beverages while hypoglycemic followed by the infusion 
of D40% causing the patients’ BSL to jump to 383 mg/dL.
There were 37 actual or potential ADR incidences, which occurred 
due to drug interaction. Incidence of interaction between diabetic–
diabetic drugs was 0.0%, diabetic–non-diabetic drug interaction was 
35.1%, and non-diabetic–non-diabetic drug interaction was 64.9%. 
An analysis performed with the Micromedex® software showed 
that non-oral (insulin)–non-diabetic drug interactions occurred 
between aspart insulin and the following drugs: ACE inhibitors 
(captopril and ramipril), which may cause hyperglycemia; quinolone 
antibiotics (levofloxacin), which may lead to increased risk of hypo/
hyperglycemia; β blockers and β1 selective (bisoprolol) lead to 
hypo/hyperglycemia and hypertension; and angiotensin II receptor 
blocker, which increases the risk of hypoglycemia. Potential UDR 
problems also occurred due to the interaction of hypoglycemic oral 
diabetic–non-diabetic drugs between sulfonylurea (metformin) and 
ACE inhibitor (ramipril) drugs. Specifically, the administration of 
both of these drugs simultaneously causes excessive hypoglycemia. 
The most common non-diabetic group of drugs that cause potential 
drug interactions among non-diabetics is antibiotics and ACE 
inhibitors. Antibiotics are a common cause of moderate-to-severe 
drug interactions [13,16].
Patients suffering from ADR allergy
ADR is a direct danger arising from normal drug also when using 
normal doses. Allergies are undesirable drug reactions mediated by 
the immune system. Treatment of a mild allergic reaction required 
discontinuation of the drug. On the contrary, for moderate-to-severe 
allergic reactions, assessment and treatment are necessary. Unsolicited 
drug reactions of severe allergies can lead to disability and even death. 
In our study, we have not observed the provision of drugs at risk of 
causing ADR allergy.
Patients suffering from toxic effects
Drug use will always pose a risk even if it is kept to a minimum. 
This is due to possible infrequent toxic reactions or side effects. All 
chemicals are toxic, and poisoning is determined by the dose and 
mode of administration [17]. DRP with a subset of patients suffering 
from potentially toxic effects occurred in 22 of the observed cases. 
Five possible causes of potentially toxic effects have been identified: 
Frequent dose regulation; pharmacokinetics-related problems 
requiring dose adjustment; inappropriate drug use/dose interval 
times; excessively high doses; and prescribing errors (in terms of drug 
prescription).
An excessively frequent dose regulation was found in omeprazole drug 
administration. We observed that omeprazole dosage was 2×40 mg 
i.v. However, the dosage should be 1×20–40 mg. It is also known that 
overdose/toxic events associated with this drug are minimal, with 
hypotension as the most common symptom.
Non-DM drugs caused the majority of toxic effects. This relates to 
pharmacokinetics-related problems that required dose adjustment 
and inappropriate drug use/interval time. There should be a dose 
adjustment for renal impairment. Calculation of creatinine clearance, 
using the Cockcroft and Gault method, found that patients with diabetic 
nephropathy complications had clearance <50 ml/min. In these cases, 
a dosage adjustment was required, administering 50 mg of ranitidine 
every 18–24 h as well as metoclopramide 25% of normal dose given 
in case of clearance <10 ml/min. An example of this occurrence was 
a 77-year-old patient with serum creatinine 3.4 mg/dL, creatinine 
clearance 9.26 ml/min, and 40 kg body weight.
Kidney damage due to DM affects the pharmacokinetics of the drug. 
Acute illness or kidney trauma will reduce glomerular filtration and/or 
active secretion, causing a longer elimination time of the drug, leading 
to a potential drug accumulation in the body and higher risk of toxic 
effects [17].
DRP caused by toxic effects of drugs was also found following ranitidine 
administration in patients suffering from diabetic nephropathy. For 
these patients, the prescription required ranitidine administration 
2×50 mg i.v. without any clear dose interval. In general, ranitidine 
administered in the cardiac is in intervals of 7–8 h.
Prescription errors (in the case of prescriptions) that have the potential 
to cause toxic effects in patients were seen with the prescription of folic 
acid 3×50 mg. Excessive folic acid can cause progressive nerve damage.
CONCLUSION
In this study, the percentage of DRP occurring amounted to 50.6% of 
therapeutic effectiveness problems and 49.4% ADR. Non-allergic ADR 
is a DRP subdomain that has the greatest frequency of occurrence 
(36.1%).
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